Inovio's vgx-3100 demonstrates positive phase 2 efficacy in treatment of precancerous anal dysplasia caused by hpv-16/18

Plymouth meeting, pa., dec. 9, 2020 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on bringing to market precisely designed dna medicines to treat and protect people from infectious diseases, cancer and diseases associated with hpv, today announced positive phase 2...
INO Ratings Summary
INO Quant Ranking